GP AKT EXAM QUESTIONS AND
ANSWERS 2026 VERIFIED.
Asthma Diagnosis with PEFR - ANS Greater than 20% variation or 60L/min on 3 days per week
Clubbing - ANS Resp - Bronchial Ca, Pulm fibrosis, Mesothelioma, TB, lung abscess,
bronchiectasis, CF, empyema
CVD - atrial myxoma, infective endocarditis, cyanotic congenital heart disease
GI - IBD, cirrhosis, malabsorption
COPD management - ANS 1. SABA or SAMA
2. LAMA or LABA if FEV1 >50%
if <50% consider combination with ICS
How long to provide a contract - ANS 2 months
How long in post before you can claim unfair dismissal - ANS 2 years
Time limit on Employment Tribunal Claim - ANS 3 months
Response within 21 days
Polymyalgia rheumatica - ANS >50yrs
bilateral shoulder/pelvic ache
@2026/2027 ALLRIGHTS RESERVED.
,raised ESR/CRP
morning stiffness
weight loss
Warfarin interactions - ANS Increased INR: Miconazole
Sensitivity - ANS How good at detecting people with the condition
true positive/number with condition
Specificity - ANS How good at excluding those without condition
true negative/number without condition
Positive predictive value - ANS Number with a positive result who actually have condition
TP/TP+FP
Negative predictive value - ANS Number with negative result actually without condition
TN/TN+FN
Likelihood ratio - ANS Compare the probability of a result if a pt has the condition vs if they
don't
+ve result = sensitivity/1-specificity
-ve result = 1-sensitivity/specificity
Legionnaire's disease - ANS Gram -ve
5% attack rate
flu-like symptoms, myalgia, confusion
@2026/2027 ALLRIGHTS RESERVED.
, Ciprofloxacin and macrolides
Mortality 15-20%
CA 27.29 - ANS Response to treatment in breast cancer
CEA - ANS colorectal ca
CA 19-9 - ANS pancreatic masses
Ca 125 - ANS hepatocellular Ca
alpha fetoprotein - ANS gestational trophoblastic disease, hepatocellular ca,
Down's syndrome cardiac defects - ANS 1. AVSD
2. VSD
3. PDA
4. Tetralogy of Fallot
5. ASD
Oral ulceration - ANS Methotrexate
Captopril
Penacillamine
Proguanil
Protease inhibitors
Gold
Nicorandil
NSAIDs
@2026/2027 ALLRIGHTS RESERVED.
ANSWERS 2026 VERIFIED.
Asthma Diagnosis with PEFR - ANS Greater than 20% variation or 60L/min on 3 days per week
Clubbing - ANS Resp - Bronchial Ca, Pulm fibrosis, Mesothelioma, TB, lung abscess,
bronchiectasis, CF, empyema
CVD - atrial myxoma, infective endocarditis, cyanotic congenital heart disease
GI - IBD, cirrhosis, malabsorption
COPD management - ANS 1. SABA or SAMA
2. LAMA or LABA if FEV1 >50%
if <50% consider combination with ICS
How long to provide a contract - ANS 2 months
How long in post before you can claim unfair dismissal - ANS 2 years
Time limit on Employment Tribunal Claim - ANS 3 months
Response within 21 days
Polymyalgia rheumatica - ANS >50yrs
bilateral shoulder/pelvic ache
@2026/2027 ALLRIGHTS RESERVED.
,raised ESR/CRP
morning stiffness
weight loss
Warfarin interactions - ANS Increased INR: Miconazole
Sensitivity - ANS How good at detecting people with the condition
true positive/number with condition
Specificity - ANS How good at excluding those without condition
true negative/number without condition
Positive predictive value - ANS Number with a positive result who actually have condition
TP/TP+FP
Negative predictive value - ANS Number with negative result actually without condition
TN/TN+FN
Likelihood ratio - ANS Compare the probability of a result if a pt has the condition vs if they
don't
+ve result = sensitivity/1-specificity
-ve result = 1-sensitivity/specificity
Legionnaire's disease - ANS Gram -ve
5% attack rate
flu-like symptoms, myalgia, confusion
@2026/2027 ALLRIGHTS RESERVED.
, Ciprofloxacin and macrolides
Mortality 15-20%
CA 27.29 - ANS Response to treatment in breast cancer
CEA - ANS colorectal ca
CA 19-9 - ANS pancreatic masses
Ca 125 - ANS hepatocellular Ca
alpha fetoprotein - ANS gestational trophoblastic disease, hepatocellular ca,
Down's syndrome cardiac defects - ANS 1. AVSD
2. VSD
3. PDA
4. Tetralogy of Fallot
5. ASD
Oral ulceration - ANS Methotrexate
Captopril
Penacillamine
Proguanil
Protease inhibitors
Gold
Nicorandil
NSAIDs
@2026/2027 ALLRIGHTS RESERVED.
